Onyda XR and ADHD Onyda XR received FDA approval for the treatment of ADHD as monotherapy or as an adjunct to stimulant medications in pediatric patients aged six and above
Kyere KA, Than KD, Wang AC, et al
Nurolac-1500 by Medlock Healthcare Medlock Healthcare is a reputed pharma firm with WHO-GMP and ISO certifications
The peptide's muscle-protective properties extend beyond genetic muscle diseases, with potential applications in preventing exercise-induced muscle damage, accelerating recovery from injury, and maintaining muscle mass during periods of disuse or immobilization
Similarly, in our current investigation, we observed that the knockdown of SLC25A39 significantly impairs cell survival and migration, strongly implicating the reduction in mitochondrial GSH import mediated by SLC25A39 knockdown in inhibiting cell survival and migration in colorectal cancer (CRC)
Molecular and Cellular Biochemistry